COMPANY
AMGEN LIMITED
AMGEN LIMITED: marketing authorisation holder for Carfilzomib, Etelcalcetide, as stated by public registers.
MARKETING AUTHORISATION HOLDER
Holds the licence to sell the medicine in a country (EMA, MHRA, Health Canada).
| Carfilzomib | KYPROLIS (CARFILZOMIB) 10 MG POWDER FOR SOLUTION FOR INFUSION, PLGB 13832/0023, Authorised Regulator MHRA |
|---|---|
| Carfilzomib | KYPROLIS (CARFILZOMIB) 30 MG POWDER FOR SOLUTION FOR INFUSION, PLGB 13832/0024, Authorised Regulator MHRA |
| Carfilzomib | KYPROLIS (CARFILZOMIB) 60 MG POWDER FOR SOLUTION FOR INFUSION, PLGB 13832/0025, Authorised Regulator MHRA |
| Etelcalcetide | PARSABIV 10 MG SOLUTION FOR INJECTION, PLGB 13832/0039, Authorised Regulator MHRA |
| Etelcalcetide | PARSABIV 2.5 MG SOLUTION FOR INJECTION, PLGB 13832/0040, Authorised Regulator MHRA |
| Etelcalcetide | PARSABIV 5 MG SOLUTION FOR INJECTION, PLGB 13832/0041, Authorised Regulator MHRA |
What a register states, not an endorsement or an accusation by this site. All companies.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.